Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Petra Kövy"'
Autor:
Petra Kövy, Zoltán Őrfi, András Bors, András Kozma, László Gopcsa, János Dolgos, Nóra Lovas, József Harasztdombi, Viktor Lakatos, Ágnes Király, Gábor Mikala, István Vályi-Nagy, Péter Reményi, Hajnalka Andrikovics
Publikováno v:
PLoS ONE, Vol 16, Iss 6, p e0253386 (2021)
Monitoring measurable residual disease (MRD) in acute myeloid leukemia (AML) plays an important role in predicting relapse and outcome. The applicability of the leukemia-initiating nucleophosmin1 (NPM1) gene mutations in MRD detection is well-establi
Externí odkaz:
https://doaj.org/article/a29c4b9b870e4ce6a27101d22d6b7a81
Autor:
Katalin Balassa, Tamás Masszi, Petra Kövy, Péter Reményi, Hajnalka Andrikovics, László Gopcsa, Árpád Bátai, János Sinkó, Melinda Paksi, Lívia Varga, Attila Tordai, Nóra Meggyesi, András Bors, Eszter Vad
Publikováno v:
Bone Marrow Transplantation. 55:215-223
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic option for malignant hematopoietic diseases. Cytokines including transforming growth factor β1 (TGFβ1) play a pivotal role in immune reconstruction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45f999345f40f3ba301cf2f2898693eb
https://doi.org/10.1038/s41409-019-0656-4
https://doi.org/10.1038/s41409-019-0656-4
Autor:
András Kozma, Péter Reményi, András Bors, Hajnalka Andrikovics, József Harasztdombi, János Dolgos, István Vályi-Nagy, Nóra Meggyesi, Gábor Mikala, Emma Ádám, Petra Kövy, Nóra Lovas, Viktor Lakatos, Adrienn Borsy
Publikováno v:
Hematológia−Transzfuziológia. 52:106-114
Absztrakt: Az izocitrat dehidrogenaz 1 es 2 szomatikus mutaciok az akut myeloid leukemia visszaterő genetikai elteresei, tagabb ertelemben vett epigenetikus hatasmoddal. Az irodalomban ellentmondo ...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77f4210d0203921100839adeff68e449
https://doi.org/10.1556/2068.2019.52.2.4
https://doi.org/10.1556/2068.2019.52.2.4
Autor:
Gabor Mikala, András Kozma, Ágnes Király, Péter Reményi, Hajnalka Andrikovics, András Bors, István Vályi-Nagy, Petra Kövy, János Dolgos, Viktor Lakatos, László Gopcsa, Zoltán Őrfi, Nóra Lovas, József Harasztdombi
Publikováno v:
PLoS ONE, Vol 16, Iss 6, p e0253386 (2021)
PLoS ONE
PLoS ONE
Monitoring measurable residual disease (MRD) in acute myeloid leukemia (AML) plays an important role in predicting relapse and outcome. The applicability of the leukemia-initiating nucleophosmin1 (NPM1) gene mutations in MRD detection is well-establi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d15c858d6f1cda383dac1b58e2e20eda
https://doaj.org/article/a29c4b9b870e4ce6a27101d22d6b7a81
https://doaj.org/article/a29c4b9b870e4ce6a27101d22d6b7a81
Autor:
Nóra Meggyesi, Katalin Piroska Kiss, Gergely Szombath, Gergely Varga, Katalin Balassa, Edit Szabó, Bálint Tegze, Tamás Masszi, Gábor Mikala, Petra Kövy, Éva Kosóczki, Attila Tordai, Hajnalka Andrikovics, László Homolya
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 17:734-742
Background Proteasome subunit beta type 1 ( PSMB1 ) rs12717 polymorphism, a single nucleotide polymorphism with unknown functional effect, was recently reported to influence response to bortezomib-based therapy in follicular lymphoma. Patients and Me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caa4b5630ef0e8d8a7287908fa026cc0
https://doi.org/10.1016/j.clml.2017.06.034
https://doi.org/10.1016/j.clml.2017.06.034
Autor:
Hajnalka, Andrikovics, Petra, Kövy, András, Bors, Dóra, Csabán, Nóra, Meggyesi, Zoltán, Õrfi, Adrienn, Borsy, András, Kozma, János, Dolgos, József, Harasztdombi, Gábor, Mikala, Péter, Reményi, István, Vályi-Nagy
Publikováno v:
Magyar onkologia. 63(4)
In contrast to solid tumours, the genetic background of acute myeloid leukemia (AML) is characterized by a relatively low number of alterations per sample (average 3-5 mutations similarly to paediatric malignancies). Although the mutational backgroun
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::82b213bbcd2f8e9f515d7b4be048e932
https://pubmed.ncbi.nlm.nih.gov/31821383
https://pubmed.ncbi.nlm.nih.gov/31821383
Autor:
Petra, Kövy, Nóra, Meggyesi, Lívia, Varga, Katalin, Balassa, András, Bors, László, Gopcsa, Melinda, Paksi, Árpád, Bátai, Eszter, Vad, János, Sinkó, Attila, Tordai, Tamás, Masszi, Péter, Reményi, Hajnalka, Andrikovics
Publikováno v:
Bone marrow transplantation. 55(1)
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a potentially curative therapeutic option for malignant hematopoietic diseases. Cytokines including transforming growth factor β1 (TGFβ1) play a pivotal role in immune reconstruction
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a5ee330a4e3729eef83700fe05013862
https://pubmed.ncbi.nlm.nih.gov/31527815
https://pubmed.ncbi.nlm.nih.gov/31527815
Autor:
László Gopcsa, Petra Kövy, András Bors, Zoltán Őrfi, Attila Tordai, Lívia Varga, Zsófia Vilimszky, Fanni Kolics, Hajnalka Andrikovics, Péter Reményi, Nóra Meggyesi
Publikováno v:
International Journal of Molecular Sciences, Vol 20, Iss 18, p 4450 (2019)
International Journal of Molecular Sciences
International Journal of Molecular Sciences
Primarily due to recent advances of detection techniques, microchimerism (the proportion of minor variant population is below 1%) has recently gained increasing attention in the field of transplantation. Availability of polymorphic markers, such as d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55873816d9463c309346651be509662d
https://doi.org/10.3390/ijms20184450
https://doi.org/10.3390/ijms20184450
Autor:
HAJNALKA, ANDRIKOVICS, PETRA, KÖVY, ANDRÁS, BORS, DÓRA, CSABÁN, NÓRA, MEGGYESI, ZOLTÁN, ŐRFI, ADRIENN, BORSY, ANDRÁS, KOZMA, JÁNOS, DOLGOS, JÓZSEF, HARASZTDOMBI, GÁBOR, MIKALA, PÉTER, REMÉNYI, ISTVÁN, VÁLYI-NAGY
Publikováno v:
Magyar Onkologia; 2019, Vol. 63 Issue 4, p282-287, 6p